Skip to main content

Table 1 Characteristics of patients in the development and validation cohorts

From: Multiparametric transrectal ultrasound for the diagnosis of peripheral zone prostate cancer and clinically significant prostate cancer: novel scoring systems

Characteristics Development cohort Validation cohort
Patients (n) 116 67
Lesions (n) 124 72
Age (years) 71.27 ± 8.50 71.73 ± 8.53
Prostate volume (mL) 61.56 ± 35.14 59.26 ± 27.42
PSA (ng/mL) 19.37 ± 20.45 22.12 ± 29.70
PSAD (ng/mL/cm3) 0.38 ± 0.44 0.43 ± 0.59
PCa, n (%) 71 (57.3) 43 (59.7)
csPCa, n (%) 55 (44.4) 37 (51.4)
MRI T-stage (n)   
 T2/T3/T4 63/8/NA 34/8/1
MRI N-stage (n)   
 N0/N1 66/5 38/5
MRI M-stage (n)   
 M0/M1 69/2 39/4
PI-RADS V2 (n)   
 2/3/4/5 27/23/39/35 15/10/27/20
Gleason score, n (%)   
 3 + 3 = 6 16 (12.9) 6 (8.3)
 3 + 4 = 7 12 (9.7) 11 (15.3)
 4 + 3 = 7 16 (12.9) 12 (16.7)
 4 + 4 = 8 18 (14.5) 5 (6.9)
 4 + 5 = 9 3 (2.4) 3 (4.2)
 5 + 4 = 9 2 (1.6) 4 (5.6)
 5 + 5 = 10 4 (3.2) 2 (2.8)
  1. PCa prostate cancer, csPCa clinically significant prostate cancer, PSA prostate-specific antigen, PSAD prostate-specific antigen density, NA not available